Month: January 2025

SIKA EXPANDS ITS GLOBAL FOOTPRINT WITH NEW PLANTS IN SINGAPORE AND CHINA Sika has opened two state-of-the-art plants in Singapore and in Xi’an, Northwest China. The newly built plant in Singapore specializes in the production of mortars, while the Xi’an facility manufactures a full range of Sika products, including tile adhesives, cementitious waterproofing, and flooring solutions. With both plants, Sika will be able to respond better to local market demands, while significantly reducing logistical distances. The highly automated plant in Singapore will cater to local customers in the metropolitan area, home to over six million people. While extensive urban planning has created many green and recreational spaces, Singapore remains the third most densely populated country in the world. This high population density creates a...

PRESS RELEASEJanuary 16, 202520250116_Press Release_Renault Group_2024 Sales Results IN 2024, ALL THE GROUP’S BRANDS ARE GROWING THANKS TO 10 LAUNCHESIn 2024, Renault Group sold 2,264,815 vehicles (+1.3% vs. 2023) worldwideRenault: 1,577,351 vehicles (+1.8% vs. 2023) Dacia: 676,340 vehicles (+2.7% vs. 2023) Alpine: 4,585 vehicles (+5.9% vs. 2023)In Europe1, the Group progressed twice as well as the market, with sales up 3.5%. With 1,599,051 vehicles sold, Renault Group is on the podium of car manufacturers with Sandero as the best-selling car across all channels. Outside Europe, with its International Game Plan, the Renault brand saw its sales increase in Brazil (+10.3%) thanks to Kardian and in South Korea (+80.6%) thanks to the launch of Grand Koleos, the first vehicle of the new Renault Korea entity. The Group...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR 16 JANUARY 2025 RICHEMONT REPORTS STRONG PERFORMANCE WITH SALES UP 10% FOR ITS THIRD QUARTER ENDED 31 DECEMBER 2024 Highlights for the quarter ended 31 December 2024Very solid end to the calendar year with Q3 sales up by 10% at constant and actual exchange ratesHighest ever quarterly sales at € 6.2 billion Double-digit growth in the Americas, Europe, Middle East & Africa and Japan; slower decline in Asia Pacific despite still challenging demand in China Marked improvement over H1 across all business areas, driven by an acceleration at Jewellery Maisons to +14%; Specialist Watchmakers at -8%, ‘Other’ at +11%, including Fashion & Accessories Maisons at +7% Channel performance led by retail, up 11% at constant and actual exchange rates9-month sales at € 16.2 billion, +4% at constant...

Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends AGAMREE® (vamorolone) for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older. This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch preparations for AGAMREE in the UK and expect first sales in this quarter. AGAMREE is the first and only medicinal product for DMD to have received...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently exercised outstanding warrants held in Santhera on a cashless basis, reinforcing its position as a major shareholder in the Company. Idorsia transfers rights to royalties and milestones for AGAMREE (vamorolone) to R-Bridge Healthcare Fund through a monetization agreement In 2020, Idorsia’s license, collaborative development, and commercialization agreement with ReveraGen BioPharma for AGAMREE was transferred in its entirety to Santhera. As part of this agreement, Idorsia is entitled to development and sales milestones, as well as low single-digit percentage royalties on net...

Harvest volumes Q4 2024 (1)Farming Norway 83.5 thousand tonnes   (FY: 304 thousand tonnes)Farming Scotland 17.0 thousand tonnes   (FY: 66 thousand tonnes)Farming Chile 22.5 thousand tonnes   (FY: 73 thousand tonnes)Farming Canada 5.0 thousand tonnes   (FY: 30 thousand tonnes)Farming Ireland 1.0 thousand tonnes   (FY: 9 thousand tonnes)Farming Faroes 1.0 thousand tonnes   (FY: 9 thousand tonnes)Farming Iceland (Arctic Fish) 3.5 thousand tonnes   (FY: 11 thousand tonnes)Total 133.5 thousand tonnes   (FY: 502 thousand tonnes)       Full year harvest volumes were record-high 502 thousand tonnes in 2024 versus 475 thousand tonnes in 2023, equivalent to a growth of 5.7% In connection with the presentation of the Q3 2024 results, Mowi guided a total harvest volume of 132.1k GWT for Q4 2024. Note:(1) The harvest volumes...

Cayman Islands, January 15, 2025 — Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accompanying warrant. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about January 17, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright...

Vancouver, BC, Jan. 15, 2025 (GLOBE NEWSWIRE) — Spirit Blockchain Capital Inc. (CSE: SPIR) (“Spirit” or the “Company”), announces the successful execution of its previously announced debt conversion with EOS Network Ventures, marking a significant milestone in Spirit’s strategic growth plan. This transaction not only strengthens Spirit’s balance sheet but also validates the Company’s innovative approach to blockchain asset management and yield-generation strategies. The Company has completed the issuance of 6,470,588 common shares (“Common Shares”) at a price of $0.17 per share to settle the $1,100,000 debt obligation to EOS Network Ventures (the “Debt Conversion”). This conversion demonstrates the strong confidence both parties share in Spirit’s future growth trajectory and operational strategy. “The successful execution of this...